Solvent Effects on Activity and Conformation of Plasminogen Activator Inhibitor-1

Summary

We have studied effects of the solvent composition on the activity and the conformation of human plasminogen activator inhibitor-1 (PAI-1) from HT-1080 fibrosarcoma cells. Non-ionic detergents, including Triton X-100, reduced the inhibitory activity of PAI-1 more than 20-fold at 0° C, but less than 2-fold at 37° C, while glycerol partly prevented the detergent-induced activity-loss at 0° C. The activity-loss was associated with an increase in PAI-1 substrate behaviour. Evaluating the PAI-1 conformation by proteolytic susceptibility of specific peptide bonds, we found that the V8-proteinase susceptibility of the Glu332-Ser333 (P₁₇-P₁₆) bond, part of the hinge between the reactive centre loop (RCL) and β-strand 5A, and the endoproteinase Asp-N susceptibility of several bonds in the β-strand 2A-α-helix E region were increased by detergents at both 0 and 37° C. The susceptibility of the Gln321-Ala322 and the Lys325-Val326 bonds in β-strand 5A to papain and trypsin, respectively, was increased by detergents at 0° C, but not at 37° C, showing a strict correlation between proteinase susceptibility of β-strand 5A and activity-loss at 0° C. Since the β-strand 2A-α-helix E region also showed differential susceptibility to endoproteinase Asp-N in latent, active, and reactive centre-cleaved PAI-1, we propose that a detergent-induced conformational change of the β-strand 2A-α-helix E region influences the movements of β-sheet A, resulting in a cold-induced conformational change of β-strand 5A and thereby an increased substrate behaviour at low temperatures. These results provide new information about the structural basis for serpin substrate behaviour.

• References

• 1 Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
• 2 Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
• 3 Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. A review. Int J Cancer 1997; 72: 1-22.
• 4 Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
• 5 Huber R, Carrell RW. Implications of the three-dimensional structure of α₁-antitrypsin for structure and functions of serpins. Biochemistry 1989; 28: 8951-66.
• 6 Carrell RW, Stein PE. The biostructural pathology of the serpins: critical functions of sheet opening mechanism. Biol Chem Hoppe-Seyler 1996; 377: 1-17.
• 7 Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
• 8 Wilczynska M, Fa M, Ohlsson I P, Ny T. The inhibition mechanism of ser-pins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270: 29652-5.
• 9 Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 1998; 37: 6375-9.
• 10 Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-protease complex formation. Proc Natl Acad Sci USA 1997; 94: 453-8
• 11 Wilczynska M, Fa M, Karolin J, Ohlsson PI, Johansson LBÅ, Ny T. Struc tural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol 1997; 4: 354-7.
• 12 Stein PE, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-21.
• 13 Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA. Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-center-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-85.
• 14 Plotnick I M, Mayne L, Schechter NM, Rubin H. Distortion of the active site of chymotrypsin complexed with a serpin. Biochemistry 1996; 35: 7586-90.
• 15 Kaslik G, Patthy A, Bálint M, László G. Trypsin complexed with α₁-proteinase inhibitor has an increased structural flexibility. FEBS Lett 1995; 370: 179-83.
• 16 Kaslik G, Kardos J, Szabo E, Szilagyi L, Zavodszky P, Westler WM, Markley JL, Graf L. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 1997; 36: 5455-64.
• 17 Stavridi ES, O´Malley K, Lukacs CM, Moore WT, Lambris JD, Christianson DW, Rubin H, Cooperman BS. Structural change in α-chymotrypsin induced by complexation with α₁-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 1996; 35: 10608-15.
• 18 Gils A, Declerck PJ. Modulation of plasminogen activator inhibitor 1 by Triton X-100. Identification of two consecutive conformational transitions. Thromb Haemost 1998; 80: 286-91.
• 19 Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen activator inhibitor-1. Eur J Biochem 1996; 241: 38-46.
• 20 Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
• 21 Kjøller L, Kanse SM, Kirkegaard T, Rodenburg KW, Rønne E, Goodmann SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
• 22 Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and amino-terminal heterogeneity, determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
• 23 Grøndahl-Hansen J, Nielsen LS, Kristensen P, Grøndahl-Hansen V, Andreasen PA, Danø K. Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 1985; 113: 257-63.
• 24 Urano T, Strandberg L, Johansson LBÅ, Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Eur J Biochem 1992; 209: 985-92.
• 25 Helenius A, Simons K. Solubilization of membranes by detergents. Biochim Biophys Acta 1975; 415: 29-79.
• 26 Gekko K, Timasheff SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 1981; 20: 4667-76.
• 27 Gekko K, Timasheff SN. Thermodynamic and kinetic examination of protein stabilization by glycerol. Biochemistry 1981; 20: 4677-86.
• 28 Hubbard SJ, Eisenmenger F, Thornton JM. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Science 1994; 3: 757-68.
• 29 Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-8.